SCHEMBL7052807

SCHEMBL7052807

CCCCc1ncc(/C=C(\Cc2ccc3c(c2)OCO3)C(=O)O)n1Cc1ccccc1Cl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7052812 1.00 — —
SCHEMBL9511004 0.93 AGTR1 (0.63) —
SCHEMBL8160507 0.90 AGTR1 (0.58) —
SCHEMBL8160504 0.90 AGTR1 (0.58) —
SCHEMBL9424338 0.88 — —
SCHEMBL9424094 0.87 — —
SCHEMBL9424090 0.87 — —
SCHEMBL9424088 0.87 — —
SCHEMBL9424093 0.87 — —
SCHEMBL9424164 0.85 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5312828-A Substituted imidazoles having angiotensin II receptor blocking activity SMITHKLINE BEECHAM CORPORATION A CORP. OF PENNSYLVANIA 1994-05-17 — — US claimed
EP-0403158-A2 Imidazolyl-alkenoic acids SMITHKLINE BEECHAM CORPORATION (US) 1990-12-19 — — EP claimed
US-20030187044-A1 Medicament SMITHKLINE BEECHAM P.L.C. 2003-10-02 — — US disclosed
US-20030166700-A1 Administering a substituted imidazoles to a mammal for the treatment of athroma progression and regression SMITHKLINE BEECHAM P.L.C. 2003-09-04 — — US disclosed
US-20030096851-A1 Medicament SMITHKLINE BEECHAM P.L.C. 2003-05-22 — — US disclosed
EP-0724387-B1 ANGIOTENSION II RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CHRONIC ANTI-INFLAMMATORY DISEASES SMITHKLINE BEECHAM CORP (US) 2003-05-02 — — EP disclosed
US-20030069293-A1 Medicament SMITHKLINE BEECHAM PLC 2003-04-10 — — US disclosed
US-20030050285-A1 Substituted imidazoles; angiotensin II receptor antagonist for the treatment of hemorrhagic stroke SMITHKLINE BEECHAM P.L.C. 2003-03-13 — — US disclosed
US-20020160985-A1 Medicament SMITHKLINE BEECHAM PLC 2002-10-31 — — US disclosed
US-20020132840-A1 Treating angina in a mammal by administering an angiotensin II receptor antagonist. SMITHKLINE BEECHAM P.1.C. 2002-09-19 — — US disclosed
US-20020128300-A1 Treating diabetic retinopathy in a mammal by administering an angiotensin II receptor antagonist. SMITHKLINE BEECHAM P.L.C. 2002-09-12 — — US disclosed
WO-1992010185-A1 USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE PREVENTION OF RESTINOSIS SMITHKLINE BEECHAM PLC (GB) 1992-06-25 — — WO disclosed
WO-1992010184-A1 USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF ATHEROMA SMITHKLINE BEECHAM PLC (GB) 1992-06-25 — — WO disclosed
WO-1992010183-A1 USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF DIABETIC RETINOPATHY SMITHKLINE BEECHAM PLC (GB) 1992-06-25 — — WO disclosed
WO-1992010186-A1 USE OF ANGIOTENSN II RECEPTOR ANTAGONISTS FOR THE PREPARATION OF A MEDICAMENT FOR IMPROVING COGNITIVE FUNCTION SMITHKLINE BEECHAM PLC (GB) 1992-06-25 — — WO disclosed
WO-1992010097-A1 ANGIOTENSIN II RECEPTOR BLOCKING COMPOSITIONS SMITHKLINE BEECHAM CORPORATION (US) 1992-06-25 — — WO disclosed
WO-1992010179-A1 USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF MACULAR DEGENERATION SMITHKLINE BEECHAM PLC (GB) 1992-06-25 — — WO disclosed
WO-1992010180-A1 USE OF ANGIOTENSIN II ANTAGONIST IN THE TREATMENT OF INFARCTION SMITHKLINE BEECHAM PLC (GB) 1992-06-25 — — WO disclosed
WO-1992010182-A1 USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF DIABETIC NEPHROPATHY SMITHKLINE BEECHAM PLC (GB) 1992-06-25 — — WO disclosed
EP-0403158-A2 Imidazolyl-alkenoic acids SMITHKLINE BEECHAM CORPORATION (US) 1990-12-19 — — EP disclosed
Send feedback